MET: A new promising biomarker in non-small-cell lung carcinoma

Pharmacogenomics

Volumn 16, Issue 6, 2015, Pages 631-647

  Pérez Ramírez, Cristina ^a,b   Canãdas Garre, Marisa ^a   Jiménez Varo, Enrique ^a,b   Faus Dáder, Mariá José ^b   Calleja Hernández, Miguel Ángel ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

EGFR; MET; pharmacogenetics; resistance; targeted therapies; TKI

Indexed keywords

CABOZANTINIB; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; K RAS PROTEIN; ONARTUZUMAB; PLACEBO; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; BIOLOGICAL MARKER; GENETIC MARKER; MET PROTEIN, HUMAN;

CANCER RESISTANCE; CHROMOSOME 7Q; EGFR GENE; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG ADENOCARCINOMA; MET PROTOONCOGENE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC MARKER; GENETICS; LUNG NEOPLASMS; MUTATION;

BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84929454614     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.11     Document Type: Review

References (178)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014.
2. CA Cancer J. Clin. 64(1), 9-29 (2014).
3. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. (7th Edition).649 (2010).
4. Herbst RS1, Heymach JV, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367-1380 (2008).
5. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83(5), 584-594 (2008).
6. Kelly K, Crowley J, Bunn PA, Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19(13), 3210-3218 (2001).
7. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002).
8. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
9. Fossella F, Pereira JR, Von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003).
10. Han SW, Kim TY, Hwang PG et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23(11), 2493-2501 (2005).
11. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23(11), 2513-2520 (2005).
12. Takano T, Ohe Y, Sakamoto H et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(28), 6829-6837 (2005).
13. Taron M, Ichinose Y, Rosell R et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11(16), 5878-5885 (2005).
14. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58(1), 95-103 (2007).
15. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
16. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
17. Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized Phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann. Oncol. 24(1), 54-59 (2013).
18. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
19. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
20. Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28(2), 357-360 (2010).
21. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
22. Thomson S, Buck E, Petti F et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65(20), 9455-9462 (2005).
23. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51(2), 181-191 (2006).
24. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), e17 (2005).
25. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890-2896 (2007).
26. Lim WT, Zhang WH, Miller CR et al. PTEN and phosphorylated AKT expression and prognosis in early-and late-stage non-small cell lung cancer. Oncol. Rep. 17(4), 853-857 (2007).
27. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 18(18), 4910-4918 (2012).
28. Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci USA 109(31), E2127-E2133 (2012).
29. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
30. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68(22), 9479-9487 (2008).
31. Byers LA, Diao L, Wang J et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19(1), 279-290 (2013).
32. Wu F, Li J, Jang C, Wang J, Xiong J. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma. Int. J. Clin. Exp. Pathol. 7(10), 6653-6661 (2014).
33. Zhang Z, Lee JC, Lin L et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44(8), 852-860 (2012).
34. Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J. Clin. Oncol. 29(36), 4837-4838 (2011).
35. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci USA 104(52), 20932-20937 (2007).
36. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075 (2008).
37. Krishnaswamy S, Kanteti R, Duke-Cohan JS et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin. Cancer Res. 15(18), 5714-5723 (2009).
38. Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65(4), 1479-1488 (2005).
39. Cooper CS, Park M, Blair DG et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311(5981), 29-33 (1984).
40. Duh FM, Scherer SW, Tsui LC, Lerman MI, Zbar B, Schmidt L. Gene structure of the human MET proto-oncogene. Oncogene 15(13), 1583-1586 (1997).
41. Liu Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 215(1), 159-169 (1998).
42. Comoglio PM, Boccaccio C. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells 1(4), 347-354 (1996).
43. Maestrini E, Tamagnone L, Longati P et al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc. Natl Acad. Sci USA 93(2), 674-678 (1996).
44. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 63(2), 169-179 (2009).
45. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22(4), 309-325 (2003).
46. Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 280(1), 1-14 (2009).
47. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12(2), 89-103 (2012).
48. Abella JV, Peschard P, Naujokas MA et al. Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell Biol. 25(21), 9632-9645 (2005).
49. Gandino L, Longati P, Medico E, Prat M, Comoglio PM. Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase. J. Biol. Chem. 269(3), 1815-1820 (1994).
50. Petrelli A, Gilestro GF, Lanzardo S, Comoglio PM, Migone N, Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature 416(6877), 187-190 (2002).
51. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416(6877), 183-187 (2002).
52. Fournier TM, Kamikura D, Teng K, Park M. Branching tubulogenesis but not scatter of madin-darby canine kidney cells requires a functional Grb2 binding site in the Met receptor tyrosine kinase. J. Biol. Chem. 271(36), 22211-22217 (1996).
53. Weidner KM, Sachs M, Riethmacher D, Birchmeier W. Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells. Proc. Natl Acad. Sci USA 92(7), 2597-2601 (1995).
54. Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 9(7), 2019-2027 (1994).
55. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11(12), 834-848 (2010).
56. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19(49), 5582-5589 (2000).
57. Ponzetto C, Bardelli A, Zhen Z et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77(2), 261-271 (1994).
58. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int. J. Biochem. Cell Biol. 31(12), 1357-1362 (1999).
59. Gherardi E, Sandin S, Petoukhov MV et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl Acad. Sci USA 103(11), 4046-4051 (2006).
60. Maina F, Casagranda F, Audero E et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 87(3), 531-542 (1996).
61. Zanetti A, Stoppacciaro A, Marzullo A et al. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J. Pathol. 186(3), 287-291 (1998).
62. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J. Cell Biol. 123(1), 223-235 (1993).
63. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF chain in complex with the Sema domain of the Met receptor. EMBO J. 23(12), 2325-2335 (2004).
64. Gelsomino F, Facchinetti F, Haspinger ER et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit. Rev. Oncol. Hematol. 89(2), 284-299 (2014).
65. Andermarcher E, Surani MA, Gherardi E. Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev. Genet. 18(3), 254-266 (1996).
66. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8(10), 404-410 (1998).
67. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376(6543), 768-771 (1995).
68. Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119(3), 629-641 (1992).
69. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27(1), 85-94 (2008).
70. Huh C-G, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci USA 101(13), 4477-4482 (2004).
71. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr. Opin. Genet. Dev. 18(1), 87-96 (2008).
72. Schmidt C, Bladt F, Goedecke S et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373(6516), 699-702 (1995).
73. Streit A, Stern CD, Thery C et al. A role for HGF/SF in neural induction and its expression in Hensen's node during gastrulation. Development 121(3), 813-824 (1995).
74. Takayama H, La Rochelle WJ, Anver M, Bockman DE, Merlino G. Scatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest development. Proc. Natl Acad. Sci. USA 93(12), 5866-5871 (1996).
75. Uehara Y, Minowa O, Mori C et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373(6516), 702-705 (1995).
76. Van Der Voort R, Taher TE, Derksen PW, Spaargaren M, Van Der Neut R, Pals ST. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv. Cancer Res. 79, 39-90 (2000).
77. Van Der Voort R, Taher TE, Keehnen RM, Smit L, Groenink M, Pals ST. Paracrine regulation of germinal center B cell adhesion through the c-met-hepatocyte growth factor/scatter factor pathway. J. Exp. Med. 185(12), 2121-2131 (1997).
78. Ikehara S. Role of hepatocyte growth factor in hemopoiesis. Leuk. Lymphoma 23(3-4), 297-303 (1996).
79. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4(12), 915-925 (2003).
80. Boccaccio C, Ando M, Tamagnone L et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391(6664), 285-288 (1998).
81. Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J. Biol. Chem. 271(22), 13116-13122 (1996).
82. Fixman ED, Naujokas MA, Rodrigues GA, Moran MF, Park M. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus. Oncogene 10(2), 237-249 (1995).
83. Maroun CR, Holgado-Madruga M, Royal I et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell Biol. 19(3), 1784-1799 (1999).
84. Ponzetto C, Bardelli A, Maina F et al. A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol. Cell Biol. 13(8), 4600-4608 (1993).
85. Stefan M, Koch A, Mancini A et al. Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis. J. Biol. Chem. 276(5), 3017-3023 (2001).
86. Lock LS, Frigault MM, Saucier C, Park M. Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. J. Biol. Chem. 278(32), 30083-30090 (2003).
87. Lock LS, Royal I, Naujokas MA, Park M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and-independent recruitment of Gab1 to receptor tyrosine kinases. J. Biol. Chem. 275(40), 31536-31545 (2000).
88. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF-and insulin-receptor signalling. Nature 379(6565), 560-564 (1996).
89. Lamorte L, Rodrigues S, Naujokas M, Park M. Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the met morphogenic program. J. Biol. Chem. 277(40), 37904-37911 (2002).
90. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell Biol. 20(22), 8513-8525 (2000).
91. Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149(7), 1419-1432 (2000).
92. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384(6605), 173-176 (1996).
93. Fournier TM, Lamorte L, Maroun CR et al. Cbl-transforming variants trigger a cascade of molecular alterations that lead to epithelial mesenchymal conversion. Mol. Biol. Cell. 11(10), 3397-3410 (2000).
94. Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP. Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis. Oncogene 18(22), 3399-3406 (1999).
95. Fan S, Ma YX, Wang JA et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3 kinase. Oncogene 19(18), 2212-2223 (2000).
96. Nakanishi K, Fujimoto J, Ueki T et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin. Exp. Metastasis 17(6), 507-514 (1999).
97. Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell. 9(8), 2185-2200 (1998).
98. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl Acad. Sci. USA 98(1), 247-252 (2001).
99. Chen HC, Chan PC, Tang MJ, Cheng CH, Chang TJ. Tyrosine phosphorylation of focal adhesion kinase stimulated by hepatocyte growth factor leads to mitogen-activated protein kinase activation. J. Biol. Chem. 273(40), 25777-25782 (1998).
100. Gual P, Giordano S, Williams TA, Rocchi S, Van Obberghen E, Comoglio PM. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19(12), 1509-1518 (2000).
101. Kodama A, Takaishi K, Nakano K, Nishioka H, Takai Y. Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells. Oncogene 18(27), 3996-4006 (1999).
102. Lai JF, Kao SC, Jiang ST, Tang MJ, Chan PC, Chen HC. Involvement of focal adhesion kinase in hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells. J. Biol. Chem. 275(11), 7474-7480 (2000).
103. Lamorte L, Kamikura DM, Park M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 19(52), 5973-5981 (2000).
104. Lamorte L, Rodrigues S, Sangwan V, Turner CE, Park M. Crk associates with a multimolecular Paxillin/GIT2/beta-PIX complex and promotes Rac-dependent relocalization of Paxillin to focal contacts. Mol. Biol. Cell. 14(7), 2818-2831 (2003).
105. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol. Cell Biol. 15(2), 1110-1122 (1995).
106. Royal I, Lamarche-Vane N, Lamorte L, Kaibuchi K, Park M. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol. Biol. Cell. 11(5), 1709-1725 (2000).
107. Sakkab D, Lewitzky M, Posern G et al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J. Biol. Chem. 275(15), 10772-10778 (2000).
108. Hammond DE, Urbe S, Vande Woude GF, Clague MJ. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20(22), 2761-2770 (2001).
109. Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3(6), 519-523 (2003).
110. Machide M, Hashigasako A, Matsumoto K, Nakamura T. Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase. J. Biol. Chem. 281(13), 8765-8772 (2006).
111. Palka HL, Park M, Tonks NK. Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1. J. Biol. Chem. 278(8), 5728-5735 (2003).
112. Sangwan V, Paliouras GN, Abella JV et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J. Biol. Chem. 283(49), 34374-34383 (2008).
113. Gandino L, Di Renzo MF, Giordano S, Bussolino F, Comoglio PM. Protein kinase-c activation inhibits tyrosine phosphorylation of the c-met protein. Oncogene 5(5), 721-725 (1990).
114. Gandino L, Munaron L, Naldini L, Ferracini R, Magni M, Comoglio PM. Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene. J. Biol. Chem. 266(24), 16098-16104 (1991).
115. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 16(1), 37-45 (2010).
116. Turner FE, Broad S, Khanim FL et al. Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes. J. Biol. Chem. 281(30), 21321-21331 (2006).
117. Mejlvang J, Kriajevska M, Vandewalle C et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. Mol. Biol. Cell. 18(11), 4615-4624 (2007).
118. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
119. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
120. Hu B, Guo P, Bar-Joseph I et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 26(38), 5577-5586 (2007).
121. Tamagnone L, Artigiani S, Chen H et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 99(1), 71-80 (1999).
122. Birchmeier W, Brinkmann V, Niemann C et al. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Found. Symp. 212, 230-240; discussion 240-236 (1997).
123. Birchmeier W, Weidner KM, Behrens J. Molecular mechanisms leading to loss of differentiation and gain of invasiveness in epithelial cells. J. Cell Sci. Suppl. 17, 159-164 (1993).
124. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 16(10), 2634-2645 (1997).
125. Royal I, Park M. Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. J. Biol. Chem. 270(46), 27780-27787 (1995).
126. Schildhaus HU, Schultheis AM, Ruschoff J et al. MET amplification status in therapy-naive adeno-and squamous cell carcinomas of the lung. Clin. Cancer Res. 21(4), 907-915 (2014).
127. Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67(5), 2081-2088 (2007).
128. Arcila ME, Oxnard GR, Nafa K et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin. Cancer Res. 17(5), 1169-1180 (2011).
129. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3(75), 75ra26 (2011).
130. Arteaga CL. HER3 and mutant EGFR meet MET. Nat. Med. 13(6), 675-677 (2007).
131. Cappuzzo F, Janne PA, Skokan M et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 20(2), 298-304 (2009).
132. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol. Hematol. 29(3), 209-248 (1999).
133. Chen JT, Lin TS, Chow KC et al. Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells. Am. J. Respir. Cell Mol. Biol. 34(3), 264-273 (2006).
134. Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J. Biomed. Biotechnol. 2011, 165214 (2011).
135. Sequist LV, Von Pawel J, Garmey EG et al. Randomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 29(24), 3307-3315 (2011).
136. Spigel DR, Ervin TJ, Ramlau RA et al. Randomized Phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 31(32), 4105-4114 (2013).
137. Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16(1), 68-73 (1997).
138. Schmidt L, Junker K, Nakaigawa N et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18(14), 2343-2350 (1999).
139. Lee JH, Han SU, Cho H et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19(43), 4947-4953 (2000).
140. Ludovini V, Bianconi F, Pistola L et al. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother. Pharmacol. 69(5), 1289-1299 (2012).
141. Ma PC, Tretiakova MS, Mackinnon AC et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47(12), 1025-1037 (2008).
142. Park WS, Dong SM, Kim SY et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59(2), 307-310 (1999).
143. Seiwert TY, Jagadeeswaran R, Faoro L et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69(7), 3021-3031 (2009).
144. Zeng ZS, Weiser MR, Kuntz E et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265(2), 258-269 (2008).
145. Kong-Beltran M, Seshagiri S, Zha J et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 66(1), 283-289 (2006).
146. Lorenzato A, Olivero M, Patanè S et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 62, 7025-7030 (2002).
147. Hellerstedt BA, Edelman G, Vogelzang Nj et al. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 30(Suppl.), Abstract 7514 (2012).
148. Mok T, Tan E, Park K. Randomized Phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J. Clin. Oncol. 29(Suppl.), Abstract TPS213 (2012).
149. Scagliotti G, Novello S, Ramlau R et al. Results of the Phase 3 MARQUEE study: MET inhibitor tivantinib (ARQ 197) plus erlotinib vs erlotinib plus placebo in NSCLC. Proceedings of 17th ECCO-38th ESMO-32nd ESTRO European Cancer Congress (2013) (Abstract E17-1821).
150. Scagliotti GV, Novello S, Schiller JH et al. Rationale and design of MARQUEE: a Phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin. Lung Cancer 13(5), 391-395 (2012).
151. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368(25), 2385-2394 (2013).
152. Davidenko I, Ivenson T, Donehower RC, Tjulandin S, Deptala A. Updated efficacy, biomarker, and exposure-response data from a Phase 2 study of rilotumumab plus epirubicin, cisplatin, and capecitabine in gastric or esophagogastric junction cancer. Presented at: European Society for Medical Oncology Congress, 28 September-2 October 2012.
153. Oliner KS, Tang R, Anderson A, Lan Y, Ivenson T. Evaluation of MET pathway biomarkers in a Phase 2 study of rilotumumab or placebo in combination with epirubicin/cisplatin/capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. Presented at: Annual Meeting of the American Society of Clinical Oncology 1-5 June 2012.
154. Oliner KS, Tang R, Anderson A et al. Evaluation of MET pathway biomarkers in a Phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J. Clin. Oncol. 30(Suppl.), Abstract 4005 (2012).
155. D'Arcangelo M, Cappuzzo F. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics 7, 61-68 (2013).
156. Tan E, Park K, Lim WT et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J. Clin. Oncol. 2011(Suppl.), Abstract 7571 (2011).
157. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol. Ther. 142(3), 316-338 (2014).
158. Spigel D, Edelman M, O'Byrne K et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal Phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J. Clin. Oncol. 32(5 Suppl.) (2014).
159. Eathiraj S, Palma R, Volckova E et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J. Biol. Chem. 286(23), 20666-20676 (2011).
160. Kyowa Hakko Kirin Co Ltd. Kyowa Hakko Kirin Co Ltd announces discontinuation of Phase 3 clinical trial for ARQ 197 (Tivantinib) in combination with eroltinib in non-small-cell lung cancer patients. www.kyowa-kirin.com
161. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10(12), 2298-2308 (2011).
162. Wakelee H, Gettinger S, Engelman J et al. A Phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28(Suppl.), Abstract 3017 (2010).
163. Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 40(2), 300-306 (2014).
164. Abecasis GR, Auton A, Brooks LD et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 491(7422), 56-65 (2012).
165. Cui JJ, Tran-Dube M, Shen H et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54(18), 6342-6363 (2011).
166. Kwak EL, Camidge D, Clark J et al. Clinical activity observed in a Phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27(Suppl. 15), Abstract 3509 (2009).
167. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67(9), 4408-4417 (2007).
168. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6(5), 942-946 (2011).
169. Chi AS, Kwak E, Clark J et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J. Clin. Oncol. 29(Suppl.), Abstract 2072 (2011).
170. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29(36), 4803-4810 (2011).
171. Palma NA, Ali SM, O'connor J et al. Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary. Case Rep. Oncol. 7(2), 503-508 (2014).
172. Stein MN, Hirshfield KM, Zhong H, Singer EA, Ali SM, Ganesan S. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. Eur Urol. pii:S0302-2838(14)01020-3 (2014) (Epub ahead of print).
173. Qian F, Engst S, Yamaguchi K et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69(20), 8009-8016 (2009).
174. Choueiri TK, Vaishampayan U, Rosenberg JE et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J. Clin. Oncol. 31(2), 181-186 (2013).
175. Burbridge MF, Bossard CJ, Saunier C et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. 12(9), 1749-1762 (2013).
176. Shin JS, Hong SW, Moon JH et al. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest. New Drugs 32(3), 389-399 (2014).
177. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8(9), 709-723 (2009).
178. ISRCTN-ISRCTN00759419: Phase I dose-escalation study of S 49076 in patients with advanced solid tumors (13/01/2015) (2015). www.isrctn.com/ISRCTN00759419